bioMérieux S.A. (0RUG.L)
| Previous close | 104.84 |
| Open | 104.95 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 104.95 - 105.30 |
| 52-week range | 77.50 - 105.30 |
| Volume | |
| Avg. volume | 52,233 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireOxford Nanopore and bioMérieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics
OXFORD, England & MARCY-L’ETOILE, France, April 14, 2023--Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a world leader in the field of in vitro diagnostics, today announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.
PR NewswirebioMérieux Introduces GENE-UP® ENVIROPRO™
bioMérieux, a world leader in in vitro diagnostics, announces the availability of GENE-UP® ENVIROPRO™, the only assay of its kind to simultaneously detect both Salmonella and Listeria from environmental swabbing, including PCR confirmation. The solution provides cost savings, laboratory waste reduction, and a streamlined workflow to empower rapid and effective quality decisions.
